[O6] Oral Session 6　Lung Cancer / Thoracic Cancer 1（Molecularly-targeted therapy EGFR, ALK）
【E】

[O6-6] Resistance mechanisms to alectinib in pts with ALK+ NSCLC: interim data of the multicenter observational study (ALCURE)

^○Naoki Haratake¹, Khin Kyaemon Thwin², Mei Matsumoto², Yasutaka Watanabe³, Hirotsugu Kenmotsu⁴, Shoichi Itoh⁵, Ken Uchibori⁶, Ayako Shiono⁷, Aoi Hino⁸, Toshihide Yokoyama⁹, Yukihiro Toi¹⁰, Hisashi Tanaka¹¹, Hidetoshi Hayashi¹², Eisaku Miyauchi¹³, Naoki Ishizuka¹⁴, Yusuke Kajihara¹⁵, Yuki Nakagawa¹⁶, Kazuma Kiyotani¹⁷, Siew-Kee Low¹⁷, Ryohei Katayama² (1.Department of Surgery and Science, Kyushu University Hospital, 2.Div of Experimental Chemotherapy, The Cancer Chemotherapy Center of JFCR, 3.Division of Thoracic Oncology, Saitama Cancer Center, 4.Division of Thoracic Oncology, Shizuoka Cancer Center, 5.Department of Thoracic Oncology, Hyogo Cancer Center, 6.Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR, 7.Department of Respiratory Medicine, Saitama Medical University International Medical Center, 8.Department of Respiratory Medicine, Chiba University Hospital, 9.Department of Respiratory Medicine, Kurashiki Central Hospital, 10.Department of Respiratory Medicine, Sendai Kousei Hospital, 11.Department of Respiratory Medicine, Hirosaki University Hospital, 12.Department of Medical Oncology, Kindai University Hospital, 13.Department of Respiratory Medicine, Tohoku University Hospital, 14.Department of Clinical Trial planning and Management, The Cancer Institute Hospital of JFCR, 15.Medical Science Dept., Chugai Pharmaceutical Co., Ltd., 16.Biometrics Dept., Chugai Pharmaceutical Co., Ltd., 17.The Cancer Precision Medicine Center of JFCR)